Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmental corona defines the in vivo ecotoxicity of polymeric and metal-based nanoparticles in the sea urchin Paracentrotus lividus.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

Effects of Fluoxetine on Cognitive Functioning in Children with Down Syndrome: A Prospective Open-Label Exploratory Study of Safety and Efficacy.

Journal of child and adolescent psychopharmacology·2026
Same author

Investigating the role of neuroglobin in cholesterol metabolism: a spotlight on brain-derived cells.

Lipids in health and disease·2026
Same author

CHK1 as a Metabolic and Immunological Regulator: Implications for Cancer Therapy.

Oncology research·2026
Same author

Gold Nanorod-Radiopharmaceutical Conjugates for Nuclear Medicine Theranostics: A Methodological and Multiscale Perspective.

International journal of molecular sciences·2026
Same author

Synthesis, Structural Insights, and In Vitro Evaluation of Novel Silver Complexes Supported by Amantadine-Functionalized Bis(pyrazolyl)acetate Ligands as Anticancer Agents.

ACS omega·2026

Related Experiment Video

Updated: May 26, 2026

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

Functional polymeric nanoparticles for dexamethasone loading and release.

Ilaria Fratoddi1, Iole Venditti, Cesare Cametti

  • 1Department of Chemistry, University of Rome Sapienza, Rome, Italy.

Colloids and Surfaces. B, Biointerfaces
|January 10, 2012
PubMed
Summary
This summary is machine-generated.

New copolymer nanoparticles loaded with dexamethasone (DXM) show high drug loading and controlled release. These P(PA-co-AA)@DXM nanoparticles effectively inhibit apoptosis in human tumor cells, demonstrating their biological efficacy.

More Related Videos

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Related Experiment Videos

Last Updated: May 26, 2026

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Area of Science:

  • Polymer Chemistry
  • Nanotechnology
  • Biomedical Engineering

Background:

  • Poly(phenylacetylene) (PPA) and its copolymers are explored for drug delivery applications.
  • Controlling nanoparticle properties is crucial for effective drug delivery and therapeutic outcomes.
  • Dexamethasone (DXM) is a potent anti-inflammatory and anti-cancer drug requiring efficient delivery systems.

Purpose of the Study:

  • To synthesize and characterize dexamethasone (DXM)-loaded poly(phenylacetylene-co-acrylic acid) nanoparticles (P(PA-co-AA)@DXM).
  • To investigate the drug loading capacity and release profile of the developed nanoparticles.
  • To evaluate the efficacy of P(PA-co-AA)@DXM nanoparticles in inhibiting apoptosis in human tumor cells (HeLa).

Main Methods:

  • Modified surfactant-free emulsion method for nanoparticle synthesis.
  • Scanning Electron Microscopy (SEM) and Dynamic Light Scattering (DLS) for nanoparticle characterization (size, morphology).
  • Zeta-potential measurements to determine surface charge density.
  • In vitro apoptosis inhibition assay on HeLa cells.

Main Results:

  • Synthesized P(PA-co-AA)@DXM nanoparticles with up to 90% drug loading, optimized by PA/AA ratio.
  • Characterized nanoparticles as spheres with diameters ranging from 190-500 nm, tunable by copolymer composition and DXM loading.
  • Demonstrated controlled surface charge density (0.62-2.68σ μC/m²) and confirmed the biological efficacy of DXM-loaded nanoparticles in inhibiting HeLa cell apoptosis.

Conclusions:

  • P(PA-co-AA) copolymers exhibit enhanced capability for hosting DXM, allowing control over nanoparticle size, surface functionality, charge, and release.
  • P(PA-co-AA)@DXM nanoparticles are effective in inhibiting apoptosis in human tumor cells.
  • The developed nanoparticles represent a promising platform for targeted cancer therapy.